Cadila Healthcare share price jumped over 3 percent in the morning session on November 27 after Zydus Cadila said it will apply for Phase 3 clinical trials of its experimental COVID-19 vaccine in December and expects to launch it by March 2021.
"If all goes well, the company expects to introduce the vaccine by March next year," a source told The Economic Times.
Moneycontrol could not independently verify the story.
Zydus Cadila will submit results of the Phase 2 trials next week, which "will ascertain the safety, dose and efficacy of the potential vaccine", a source said.
Initial results from the Phase 2 trials indicate that ZyCoV-D, the company's vaccine candidate, that no safety concerns were observed, the report said. According to the report, the company is looking to conduct Phase 3 trials of the vaccine against COVID-19 on 39,000 participants.
"We could be looking at manufacturing 100 million doses to begin with, once the vaccine receives all regulatory permissions," Zydus Cadila Chairman Pankaj R Patel recently told The Economic Times.
The stock was trading at Rs 436.80, up Rs 14.45, or 3.42 percent at 09:23 hours. It has touched an intraday high of Rs 441.75 and an intraday low of Rs 434.50.
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.
